Breast Cancer by AJCC v8 Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)


name: Breast Classic Lobular Carcinoma In Situ Type A

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: Breast classic lobular carcinoma in situ characterized by the presence of neoplastic cells with uniform nuclei.


name: Unresectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is not amenable to surgical resection.


Advanced Breast Carcinoma

description: Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Inflammatory carcinoma of breast stage IV

description: An inflammatory carcinoma of the breast that has spread to other anatomic sites.


name: Metastatic HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that has spread from the original site of growth to another anatomic site.


name: Prognostic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Cancer by AJCC v6 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 6th edition.


Recurrent Breast Lymphoma

description: The reemergence of breast lymphoma after a period of remission.


name: Breast Ductal Carcinoma In Situ, Low Grade

description: Breast ductal carcinoma in situ characterized by the presence of small, monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. The nuclei are uniform and mitotic figures are rare.


Locally Advanced Breast Carcinoma

description: A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Contralateral Breast Carcinoma

description: Breast carcinoma that develops in the opposite breast of a patient with an already diagnosed primary breast carcinoma.


name: Prognostic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Squamous Cell Carcinoma in the Breast

description: A squamous cell carcinoma that has spread to the breast from another anatomic site.


malignant breast melanoma

description: A melanoma that arises usually from the breast skin and less often from the breast glandular tissue. Primary breast melanomas are rare.


name: Prognostic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Oligometastatic Breast Carcinoma

description: Breast carcinoma that has metastasized to a limited number of sites.


Encapsulated Breast Papillary Carcinoma

description: Breast carcinoma characterized by the presence of fine fibrovascular stalks covered by neoplastic epithelial cells of low or intermediate nuclear grade, typically present within a cystic space and surrounded by a fibrous capsule. There are usually no myoepithelial cells along the papillae or at the periphery of the lesion. (WHO 2019)


name: Breast Carcinoma Metastatic in the Brain

description: A carcinoma that has spread to the brain from its original site in the breast, through the hematogenous route.


name: Encapsulated Breast Papillary Carcinoma with Invasion

description: Encapsulated breast papillary carcinoma characterized by the presence of neoplastic elements that permeate beyond the fibrous capsule with an irregular infiltrative appearance. (WHO 2019)


name: Breast Carcinoma with Osteoclast-Like Stromal Giant Cells

description: An invasive breast adenocarcinoma characterised by the presence of non-neoplastic stromal osteoclastic giant cells.  The carcinomatous component is usually an invasive ductal carcinoma, although all other breast adenocarcinoma subtypes have also been described.  The prognosis depends on the characteristics of the adenocarcinomatous component, and is not related to the presence of the giant cells.


Grade 2 Invasive Breast Carcinoma

description: A moderately differentiated invasive breast carcinoma.


name: Anatomic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Malignant Breast Neoplasm

description: A malignant breast neoplasm that has metastasized to another anatomic site.


Resectable Breast Carcinoma

description: Breast carcinoma that is amenable to surgical resection.


name: Low Grade Breast Mucoepidermoid Carcinoma

description: A slow growing mucoepidermoid carcinoma that arises from the breast. It is characterized by the presence of keratinization in the neoplastic squamous cells and lumina formation by glandular neoplastic cells. Complete excision may be curative.


name: Metastatic BRCA-Associated Breast Carcinoma

description: BRCA-associated breast carcinoma that has spread to another anatomic site.


Recurrent Lobular Breast Carcinoma

description: The reemergence of lobular breast carcinoma after a period of remission.


name: Estrogen Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for estrogen receptors.


name: Invasive Breast Lobular Carcinoma with Extracellular Mucin

description: A rare variant of invasive breast lobular carcinoma characterized by the presence of pools of extracellular mucin in which groups of floating lobular carcinoma cells are identified.


name: Breast Ductal Carcinoma In Situ, Intermediate Grade

description: Breast ductal carcinoma in situ characterized by the presence of monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. Intraluminal necrosis is present in some ducts. Ducts that contain neoplastic cells with occasional nucleoli and coarse chromatin may also be present.


name: Recurrent Hormone Receptor-Positive Breast Carcinoma

description: The reemergence of hormone receptor-positive breast adenocarcinoma after a period of remission.


name: adenocarcinoma of breast with squamous metaplasia

description: An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the adenocarcinoma component.


name: Recurrent Triple-Negative Breast Carcinoma

description: The reemergence of triple-negative breast carcinoma after a period of remission.


name: Metastatic Progesterone Receptor-Positive Breast Carcinoma

description: Progesterone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Breast Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma arising from the breast. It is classified as small cell or large cell neuroendocrine carcinoma.


name: Locally Advanced HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Metastatic Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Breast Ductal Carcinoma

description: A ductal breast carcinoma that has spread from the original site of growth to another anatomic site.


name: Breast Carcinoma Metastatic in the Central Nervous System

description: A carcinoma that has spread to the central nervous system from its original site in the breast, through the hematogenous route.


Recurrent Breast Tubular Carcinoma

description: The reemergence of breast tubular carcinoma after a period of remission.


Stage IIIA Breast Carcinoma

description: Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


small cell carcinoma of breast

description: A poorly differentiated neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of small neuroendocrine cells and high mitotic activity.


name: Locally Advanced Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


gamma-taxilin isoform m1 (mouse)

A gamma-taxilin (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8BHN1-1.


gamma-taxilin

A protein that is a translation product of the human TXLNG gene or a 1:1 ortholog thereof.


gamma-taxilin isoform h1 (human)

A gamma-taxilin (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NUQ3-1.


gamma-taxilin isoform h2 (human)

A gamma-taxilin (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NUQ3-2.


TXLNG_HUMAN Gamma-taxilin (sprot)

A gamma-taxilin that is encoded in the genome of human.


gamma-taxilin isoform m2 (mouse)

A gamma-taxilin (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8BHN1-2.


gamma-taxilin cysteinylated 1 (human)

A gamma-taxilin (human) that has been cysteinylated on the residue at the position equivalent to Cys-160 of the amino acid sequence represented by UniProtKB:Q9NUQ3-1. Example: UniProtKB:Q9NUQ3-1, Cys-160, MOD:00765.


gamma-taxilin isoform m3 (mouse)

A gamma-taxilin (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8BHN1-3.


Q4FZU5_RAT Similar to CXORF15 (trembl)

A gamma-taxilin that is encoded in the genome of rat.


TXLNG_MOUSE Gamma-taxilin (sprot)

A gamma-taxilin that is encoded in the genome of mouse.


Grade 5 Duodenum Necrosis, CTCAE

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing


name: OSTM1_HUMAN Osteopetrosis-associated transmembrane protein 1 (sprot)

description: An osteopetrosis-associated transmembrane protein 1 that is encoded in the genome of human.


name: osteopetrosis-associated transmembrane protein 1 methylated 1 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been methylated on the residue at the position equivalent to Cys-199 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Cys-199, MOD:00660.


name: osteopetrosis-associated transmembrane protein 1 deaminated 2 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-163 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Asn-163, MOD:00684.


name: osteopetrosis-associated transmembrane protein 1, signal peptide removed form (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has had the signal peptide removed. UniProtKB:Q86WC4, 32-334.


name: osteopetrosis-associated transmembrane protein 1 deaminated 1 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-194 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Asn-194, MOD:00684.


name: osteopetrosis-associated transmembrane protein 1 cysteinylated 1 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-199 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Cys-199, MOD:00765.


name: EMC1_CHICK ER membrane protein complex subunit 1 (sprot)

description: An ER membrane protein complex subunit 1 that is encoded in the genome of chicken.


synemin isoform m2 (mouse)

A synemin (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q70IV5-2.


SYNEM_MOUSE Synemin (sprot)

A synemin that is encoded in the genome of mouse.


synemin isoform m1 (mouse)

A synemin (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q70IV5-1.


synemin isoform m3 (mouse)

A synemin (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q70IV5-3.


A pyrazine substituted by a hydroxy group at positions 2 and 5.


LSD90_SCHPO Protein lsd90 (sprot)

A protein that is a translation product of the lsd90 gene in Schizosaccharomyces pombe 972h-.


PSA Level Less than Four

description: A blood concentration of prostate specific antigen less than 4 ng/mL.


m-azobenzenesulfonic acid

Azobenzene derivative carrying a single sulfonate substituent at the meta-position.


arenesulfonic acid

Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.


2-amino-5-nitrobenzenesulfonic acid

The arenesulfonic acid that is benzenesulfonic acid substituted at the ortho position by an amino group and at the para posiion


A member of the class of azobenzenes that is azobenzene in which one of the phenyl groups is substituted at the para position by an anilino group, while the other is substituted at a meta position by a sulfo group. The monosodium salt is the biological stain 'metanil yellow'.


azocarmine B free acid

An organic heterotetracyclic compound that is 7-phenyl-5-imino-5,7-dihydrobenzo[a]phenazine-3-sulfonic acid in which the imino hydrogen is replaced by a 2,4-disulfophenyl group. The disodium salt is the biological stain 'azocarmine B'.


indigo carmine

A member of the class of indolones obtained by formal 2,2'-oxidative coupling of two molecules of 3-oxo-2,3-dihydroindole-5-sulfonic acids.


3,4-dihydroxybenzenesulfonic acid

A benzene ring substituted with a sulphonic acid group at position C-1, and hydroxy groups at C-3 and C-4.


primuline (acid form)

A member of the class of benzothiazoles that is 2,6'-bi-1,3-benzothiazole substituted at positions 2' 6 and 7 by 4-aminophenyl, methyl and sulfo groups respectively. The monosodium salt is the biological dye 'primuline'.


A triamino-1,3,5-triazine having a polysubstituted naphthalene group attached to one of the exocyclic nitrogens.


tetrasulfocyanine acid

A arenesulfonic acid in which two sulfonated indole moieties are linked via a 4-methylhepta-1,3,5-triene-1,7-diyl chain.


Luxol fast blue MBS (acid form)

A metallophthalocyanine consisting of a phthalocyanine-disulfonic acid bound to a central copper atom. Used in the form of an arylguanidinium salt as a histological dye.


A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid carrying additional hydroxy and (2-methoxyphenyl)diazenyl substituents at positions 4 and 3 respectively. The sodium salt is the biological stain 'acid red 4'.


8-anilinonaphthalene-1-sulfonic acid

A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.


alkali Blue G

An aminobenzenesulfonic acid that is 2-aminobenzenesulfonic acid in which one of the amino hydrogens is replaced by a 4-{(4-amino-3-methylphenyl)[4-(phenylimino)cyclohexa-2,5-dien-1-ylidene]methyl} group.


ORANGE G

A naphthalenesulfonic acid that is naphthalene-1,3-disulfonic acid carrying additional hydroxy and phenyldiazenyl substituents at positions 7 and 8 respectively. The disodium salt is the biological stain 'orange G'.


lissamine fast yellow (acid form)

An arenesulfonic acid that is 2,5-dichloro-4-(pyrazol-1-yl)benzene-1-sulfonic acid in which the pyrazole ring is substituted by methyl, (4-sulfophenyl)diazenyl and hydroxy groups at positions 3, 4, and 5 respctively. The disodium salt is the biological stain 'lissamine fast yellow'.


A naphthalenesulfonic acid that is 3-(phenyldiazenyl)naphthalene-2,7-disulfonic acid carrying additional phenyldiazenyl, hydroxy and acetamido substituents at position 3, 4, and 5 respectively. The disodium salt is the biological stain 'azophloxine'.


tartrazine acid

A pyrazoles which is pyrazole-3-carboxylic acid substituted by an oxo group at position 5, a 4-sulfophenyl group at position 1 and (4-sulfophenyl)diazenyl group at position 4.


sulcofuron

An organochlorine pesticide consisting of 1,3-diphenylurea having chloro substituents at the 3-, 4- and 5'-positions and a 4-chloro-2-sulfophenoxy group at the 2'-position.


4-sulfobenzoic acid

A sulfobenzoic acid in which the sulfonic acid and carboxylic acid groups are in a para-relationship.


ferrozine free acid

An arenesulfonic acid that is the 4,4'-disulfo derivative of 5,6-diphenyl-3-(pyridin-2-yl)-1,2,4-triazine.


sulfogaiacol

An arenesulfonic acid that is guaiacol sulfated at position 4. Commonly used (in the form of its potassium salt) as an expectorant.


DOBESILIC ACID

A dihydroxybenzenesulfonic acid that is hydroquinone in which one of the phenyl hydrogens is substituted by a sulfonic acid group.


naphthalene-2,7-disulfonic acid

A naphthalenesulfonic acid in which the sulfo groups are attached to positions 2 and 7 of the naphthalene ring.


A naphthalenesulfonic acid that is naphthalene-1,3-disulfonic acid carrying additional hydroxy and (naphthalen-1-yl)diazenylsubstituents at positions 7 and 8 respectively. The disodium salt is the biological stain 'acid red 44'.


aminonaphthalenesulfonic acid

A naphthalenesulfonic acid having at least one amino substituent.


Alexa Fluor 647

An iminium betaine fluorescent dye with a max absorption wavelength 650 nm and emission wavelength 665 nm. Alexa Fluor 6 is a bright and photostable far-red dye with excitation ideally suited to the 633 nm laser line.


naphthalene blue black CS (acid form)

A bis(azo) compound that is naphthalene-2,7-disulfonic acid in which the hydrogens at positions 3, 4, 5, and 6 are replaced by (p-nitrophenyl)azo, amino, hydroxy, and (p-sulfophenyl)azo groups, respectively. The trisodium salt is the histological dye 'naphthalene blue black CS'.


p-azobenzenesulfonic acid

Azobenzene carrying a single sulfonate substituent at the para-position.


Reactive Blue 5 quinol form

An anthracene that consists of 9,10-dihydroxy-9,10-dihydroanthracene carrying amino, sulfo and [3-({4-chloro-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl}amino)-4-sulfophenyl]amino substituents at positions 1, 2 and 4 respectively.


Reactive red 120

A bis(azo) compound that consists of a benzene core having two (4-amino-6-chloro-1,3,5-triazin-2-yl)amino groups attached at positions 1 and 4 and which in turn have 5-hydroxy-6-[(2-sulfophenyl)diazenyl]-2,7-disulfonaphthalen-4-yl groups attached to their 4-amino functions.


Ponceau S (acid form)

An arenesulfonic acid that is 3-hydroxynaphthalene-2,7-disulfonic acid carrying a {2-sulfo-4-[(4-sulfophenyl)diazenyl]phenyl}diazenyl group at position 4. The tetrasodium salt is the biological stain 'Ponceau S'.


Evans blue free acid

A naphthalenesulfonic acid that is the free acid form of the dye Evans blue. The tetrasodium salt is used as a counterstain, especially in fluorescent methods to suppress background autofluorescence.


1,2-naphthoquinone-4-sulfonic acid

An arenesulfonic acid that is 1,2-naphthoquinone substituted at position 4 with a sulfonic acid group. Used principally as a reagent in colorimetric determinations.


2,4,5-trinitrobenzenesulfonic acid

An arenesulfonic acid that is benzene with a sulfo group at position 1 and three nitro substituents in the 2-, 4- and 5-positions.


chromoxane cyanin R free acid

A member of the class of benzoic acids that is 2-hydroxy-3-methyl-5-[(2-sulfophenyl)methyl]benzoic acid in which both of the benzylic hydrogens are replaced by a 3-carboxy-5-methyl-4-oxocyclohexa-2,5-dien-1-ylidene group. The trisodium salt is the biological stain 'chromoxane cyanin R'.


A naphthalenesulfonic acid that is naphthalene-2,7-disulfonic acid carrying two additional hydroxy substituents at positions 4 and 5 as well as a phenyldiazenyl substituent at position 3. The disodium salt is the biological stain 'acid red 29'.


A naphthalenesulfonic acid that is 7-hydroxynaphthalene-1,3-disulfonic acid substituted at position 8 by a [4-(phenyldiazenyl)phenyl]diazenyl group. The disodium salt is the biological stain 'woodstain scarlet'.


Durazol blue 4R (acid form)

A naphthalenesulfonic acid that is the free acid form of the dye Sirius red F3B (the trisodium salt).


Sirius scarlet GG (acid form)

An arenesulfonic acid that is 2-methoxybenzenesulfonic acid substituted at position 5 by a (4-amino-5-methoxy-2-methylphenyl)diazenyl group. The sodium salt is the histological dye 'Sirius scarlet GG'.


Sirius red 4B (acid form)

A naphthalenesulfonic acid that is 7-amino-4-hydroxy-3-({4-[(4-sulfophenyl)diazenyl]phenyl}diazenyl)naphthalene-2-sulfonic acid in which one of the amino hydrogens is replaced by a benzoyl group. The disodium salt is the histological dye 'Sirius red 4B'.


An  aminonaphthalenesulfonic acid that is 2-naphthalenesulfonic acid substituted by an amino group at position 7 and a hydroxy group at position 4 respectively.


trypan blue

An aminonaphthalenesulfonic acid that is the free acid form of trypan blue dye.


A naphthalene-1,5-disulfonic acid with an acetamido group at the 2-position.


2,4-dihydroxybenzenesulfonic acid

A dihydroxybenzenesulfonic acid that is resorcinol in which a hydrogen para- to one of the hydroxy groups is replaced by a sulfonic acid group.


naphthalene-2-sulfonic acid

A naphthalenesulfonic acid in which the sulfo group is linked to position 2 of the naphthalene ring.


azocarmine G free acid

An organic heterotetracyclic compound that is 7-phenyl-5-imino-5,7-dihydrobenzo[a]phenazine-3-sulfonic acid in which the imino hydrogen is replaced by a 4-sulfophenyl group. The monosodium salt is the biological stain 'azocarmine G'.


Reactive Red 6 hapten

A bis(azo) compound that consists of a 1,3,5-triazine core having two (5-hydroxy-1,3-disulfo-2naphthyl)amino groups at positions 2 and 6, each of which is further substituted with a 2-hydroxy-5-sulfophenylazo group.


toluene-4-sulfonic acid

An arenesulfonic acid that is benzenesulfonic acid in which the hydrogen at position 4 is replaced by a methyl group.


An  aminonaphthalenesulfonic acid fluorophore with a structure consisting of ethylenediamine substituted on the nitrogens with iodoacetyl and 5-sulfonyl-1-naphthyl groups.


lissamine fast red (acid form)

A naphthalenesulfonic acid that is 6-aminonaphthalene-2-sulfonic acid carrying additional hydroxy and (4-acetamido-2-sulfophenyl)diazenyl substituents at positions 4 and 5 respectively. The disodium salt is the biological stain 'lissamine fast red'.


Pontamine sky blue 5B (acid form)

A ring assembly consisting of two 5-amino-4-hydroxy-3-[(2-methoxyphenyl)diazenyl]naphthalene-2,7-disulfonic acid units joined by a 4,4'-linkage. The tetrasodium salt is the histological dye 'Pontamine sky blue 5B'.


egualen

A member of the class of azulenes carrying sulfo, ethyl and isopropyl substituents at positions 1, 3 and 7 respectively. Used (in the form of its sodium salt) for treatment of gastric ulcers.


dibunate

A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid which is substituted by tert-butyl groups at positions 2 and 6.


4-nitrotoluene-2-sulfonic acid

The arenesulfonic acid that is toluene-2-sulfonic acid bearing a nitro substituent at C-4.


An arenesulfonic acid that is 1,6-dihydrodibenzo[cd,g]indazole-3-sulfonic acid substituted by an oxo group at position 6.


nuclear fast red free acid

A member of the class of hydroxyanthraquinones that is 1,3-dihydroxyanthraquinone carrying additional sulfo and amino substituents at positions 2 and 4 respectively. The sodium salt is the histological dye 'nuclear fast red'


3,5-dihydroxybenzenesulfonic acid

A dihydroxybenzenesulfonic acid that is resorcinol in which the hydrogen meta- to both of the hydroxy groups is replaced by a sulfonic acid group.


name: 2-naphthalenesulfonic acid [2-[(2-amino-4-oxo-5-thiazolylidene)methyl]phenyl] ester


methyl blue free acid

An arenesulfonic acid, the disodium salt of which is the histological dye 'methyl blue' (used for staining collagen in Masson's trichrome and Mallory's method for connective tissue).


Reactive Red 6 hapten copper complex

The copper coordination entity formed from Reactive Red 6 hapten by coordination to copper of the two hydroxy groups of each phenylazo-2-naphthyl substituent.


SULFOSALICYLIC

An arenesulfonic acid that is benzoic acid substituted by a hydroxy at position C-2 and a sulfo group at C-5.


Sirius red F3B (acid form)

A naphthalenesulfonic acid that is the free acid form of the dye Sirius red F3B. The hexasodium salt is a histological dye used principally in staining methods for collagen and amyloid.


A member of the class of azobenzenes that is azobenzene in which the para position of one of the phenyl groups is substituted by a carboxy group, whilst that of the other phenyl group is substituted by a sulfo group.


anthraquinone-2,6-disulfonic acid

A member of the class of anthraquinones that is 9,10-anthraquinone substituted at positions 2 and 6 by sulfo groups.


2,6-dihydroxybenzenesulfonic acid

A dihydroxybenzenesulfonic acid that is resorcinol in which the hydrogen ortho- to both of the hydroxy groups is replaced by a sulfonic acid group.


Azobenzene substituted at C-2 of each phenyl group by a sulfo group.


2,3-dihydroxybenzenesulfonic acid

A dihydroxybenzenesulfonic acid in which the hydroxy groups are located at positions 2 and 3.


Biebrich scarlet (acid form)

An arenesulfonic acid that is m-[(4-sulfophenyl)diazenyl]benzene-1-sulfonic acid carrying a (2-hydroxynaphthalen-1-yl)diazenyl substituent at position 2. The disodium salt is the biological stain 'Biebrich scarlet'.


An  aminonaphthalenesulfonic acid fluorophore with a structure consisting of ethylenediamine substituted on the nitrogens with acetyl and 5-sulfonyl-1-naphthyl groups.


An arenesulfonic acid that is 5,6-dihydronaphthalene-2-sulfonic acid bearing hydroxyimino and oxo substituents at positions 5 and 6 respectively. The trisodium-iron(3+) salt is the biological stain 'naphthol green B'.


A diamino-1,3,5-triazine with the amino groups situated at C-2 and C-4 and with a chloro group at C-6; the amino group at C-4 is substituted with a 2-sulfophenyl group.


flavianic acid

A naphthalenesulfonic acid that is naphthalene-2-sulfonic acid substituted by nitro groups at positions 5 and 7 as well as a hydroxy group at position 8. The disodium salt is the biological stain 'naphthol yellow S'.


benzo scarlet 4BNS free acid

A naphthalenesulfonic acid that is the free acid form of the dye benzo scarlet 4BNS. The trisodium salt is a direct cotton dye that is also capable of hydrogen bonding to amyloid and giving a dark enough red colour to be useful in diagnostic histology.


drilodefensin 1

An arenesulfonic acid that is furan-3-sulfonic acid carrying hexyl and ethyl substituents at positions 2 and 5 respectively.


Amido Black 10B (acid form)

A bis(azo) compound that is naphthalene-2,7-disulfonic acid in which the hydrogens at positions 3, 4, 5, and 6 are replaced by (p-nitrophenyl)azo, amino, hydroxy, and phenylazo groups, respectively. A biological stain, it can be used interchangeably with its disodium salt, Amido Black 10B.


acid fuchsin (free acid form)

An arenesulfonic acid that is 3-[(4-amino-3-methylphenyl)(4-aminophenyl)methylidene]-6-iminocyclohexa-1,4-diene-1-sulfonic acid in which the hydrogens ortho to the amino functions are replaced by phenyl groups. The disodium salt is the biological stain 'acid fuchsin'.


A naphthalenesulfonic acid that is naphthalene-2,7-disulfonic acid carrying additional hydroxy and (2,4-dimethylphenyl)diazenyl substituents at positions 3 and 4 respectively. The disodium salt is the biological stain 'acid red 26'.


Congo corinth (acid form)

An aminonaphthalenesulfonic acid that is 3,3'-[[1,1'-biphenyl]-4,4'-diylbis(diazene-2,1-diyl)]di(naphthalene-1-sulfonic acid) in which the two hydrogens at the 4-positions on the naphthalene rings are placed by amino and hydroxy groups. The disodium salt is the histological dye 'Congo corinth'.


name: FBK66_ARATH Putative F-box/kelch-repeat protein At3g22870 (sprot)

description: A protein that is a translation product of the At3g22870 gene in Arabidopsis thaliana.


name: coagulation factor X N-glycosylated 2 (human)

description: A coagulation factor X (human) that has been N-glycosylated at the residue equivalent to Asn-221 of the amino acid sequence represented by UniProtKB:P00742-1, in which the glycan structure is represented by GlyTouCan:G24501HF. Example: UniProtKB:P00742-1, Asn-221, MOD:00160~GNO:G24501HF.


protein max isoform short (mouse)

A protein max isoform short that is encoded in the genome of mouse.


Acute prostatitis

description: An acute inflammatory process that affects the prostate gland.  It is caused by bacteria, most often Escherichia coli, Proteus mirabilis, Klebsiella, and Pseudomonas aeruginosa.


name: dimethyladenosine transferase 1, mitochondrial isoform 1

description: A dimethyladenosine transferase 1, mitochondrial that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8JZM0-1 or a 1:1 ortholog thereof.


name: dimethyladenosine transferase 1, mitochondrial isoform 1 (rat)

description: A dimethyladenosine transferase 1, mitochondrial isoform 1 that is encoded in the genome of rat.


name: dimethyladenosine transferase 1, mitochondrial isoform 1 (mouse)

description: A dimethyladenosine transferase 1, mitochondrial isoform 1 that is encoded in the genome of mouse.


name: interferon gamma isoform 1, signal peptide removed N-glycosylated 1 (human)

description: An interferon gamma isoform 1, signal peptide removed glycosylated form in human in which N-linked glycosylation occurs at Asn-48 and Asn-120. UniProtKB:P01579-1, 24-157, Asn-48/Asn-120, MOD:00160.


name: mothers against decapentaplegic homolog 4 sequence variant Q455* (human)

description: A mothers against decapentaplegic homolog 4 (human) that has has been truncated after the position equivalent to Ala-454 of the amino acid sequence represented by UniProtKB:Q13485. UniProtKB:Q13485, 1-454.


name: phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 (human)

description: A phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 that is encoded in the genome of human.


name: phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1

description: A phosphatidylinositol N-acetylglucosaminyltransferase subunit Y that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q3MUY2-1 or a 1:1 ortholog thereof.


name: phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 (mouse)

description: A phosphatidylinositol N-acetylglucosaminyltransferase subunit Y isoform 1 that is encoded in the genome of mouse.


ITB7_HUMAN Integrin beta-7 (sprot)

An integrin beta-7 that is encoded in the genome of human.


integrin beta-7 isoform Short (human)

An integrin beta-7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P26010-2.


name: integrin beta-7 isoform 1, signal peptide removed form (human)

description: An integrin beta-7 isoform 1, signal peptide removed form in human. UniProtKB:P26010-1, 20-798.


integrin beta-7 deaminated 1 (human)

An integrin beta-7 (human) that has been deaminated on the residue at the position equivalent to Asn-434 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Asn-434, MOD:00684.


integrin beta-7 isoform 1 (human)

An integrin beta-7 isoform 1 that is encoded in the genome of human.


integrin beta-7 methylated 2 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-537 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-537, MOD:00660.


integrin beta-7 methylated 5 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-271 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-271, MOD:00660.


integrin beta-7 methylated 1 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-654 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-654, MOD:00660.


integrin beta-7 methylated 3 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-670 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-670, MOD:00660.


integrin beta-7 methylated 4 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-448 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-448, MOD:00660.


LAC14_ARATH Laccase-14 (sprot)

A protein that is a translation product of the LAC14 gene in Arabidopsis thaliana.


name: Sal-like protein 4 isoform hSALL4B (human)

description: A Sal-like protein 4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UJQ4-2.


name: leucine-rich repeat LGI family member 4 isoform h2 (human)

description: A leucine-rich repeat LGI family member 4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8N135-2.


renal hypomagnesemia 4

description: Any primary hypomagnesemia in which the cause of the disease is a mutation in the EGF gene.


name: troponin T, fast skeletal muscle isoform r4 (rat)

description: A troponin T, fast skeletal muscle (rat) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P09739-4.


serine incorporator 1 isoform 1

A serine incorporator 1 that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NRX5-1 or a 1:1 ortholog thereof.


serine incorporator 1

A protein that is a translation product of the human SERINC1 gene or a 1:1 ortholog thereof.


name: SERC1_MOUSE Serine incorporator 1 (sprot)

description: A serine incorporator 1 that is encoded in the genome of mouse.


name: serine incorporator 1 cysteinylated 1 (human)

description: A serine incorporator 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-193 of the amino acid sequence represented by UniProtKB:Q9NRX5. UniProtKB:Q9NRX5, Cys-193, MOD:00765.


serine incorporator 1 isoform 1 (mouse)

A serine incorporator 1 isoform 1 that is encoded in the genome of mouse.


SERC1_RAT Serine incorporator 1 (sprot)

A serine incorporator 1 that is encoded in the genome of rat.


serine incorporator 1 isoform 1 (rat)

A serine incorporator 1 isoform 1 that is encoded in the genome of rat.


name: SERC1_HUMAN Serine incorporator 1 (sprot)

description: A serine incorporator 1 that is encoded in the genome of human.


name: serine incorporator 1 deaminated 1 (human)

description: A serine incorporator 1 (human) that has been deaminated on the residue at the position equivalent to Asn-33 of the amino acid sequence represented by UniProtKB:Q9NRX5. UniProtKB:Q9NRX5, Asn-33, MOD:00684.


serine incorporator 1 isoform 1 (human)

A serine incorporator 1 isoform 1 that is encoded in the genome of human.


name: serine incorporator 1, initiator methionine removed form (human)

description: A serine incorporator 1 (human) that has had the initiator methionine removed. UniProtKB:Q9NRX5, 2-453.


levomefolic acid

A 5-methyltetrahydrofolic acid that has 6S-configuration.


name: NACHT, LRR and PYD domains-containing protein 12 deaminated 1 (human)

description: A NACHT, LRR and PYD domains-containing protein 12 (human) that has been deaminated on the residue at the position equivalent to Asn-780 of the amino acid sequence represented by UniProtKB:P59046-1. Example: UniProtKB:P59046-1, Asn-780, MOD:00684.


name: YD157_YEAST Uncharacterized protein YDL157C, mitochondrial (sprot)

description: A protein that is a translation product of the YDL157C gene in yeast.


name: histone deacetylase 4 isoform m2 (mouse)

description: A histone deacetylase 4 (mouse) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6NZM9-2.


uncharacterized lipoprotein YajG

A protein that is a translation product of the Escherichia coli K-12 yajG gene or a 1:1 ortholog thereof.


name: YAJG_ECOLI Uncharacterized lipoprotein YajG (sprot)

description: An uncharacterized lipoprotein YajG that is encoded in the genome of Escherichia coli K-12.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1

description: A RAF proto-oncogene serine/threonine-protein kinase that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P04049-1 or a 1:1 ortholog thereof.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 in human. UniProtKB:P04049-1, Ser-259/Ser-621, MOD:00046.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that is encoded in the genome of human.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 1

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated form in which the phosphorylation occurs at two consecutive Tyr residues by active Src kinases. Example: UniProtKB:P04049-1, Tyr-340/Tyr-341, MOD:00048.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated form in which the phosphorylation occurs at two consecutive Ser residues by PAK1. Example: UniProtKB:P04049-1, Ser-338/Ser-339, MOD:00046.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 (mouse)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that is encoded in the genome of mouse.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 in human. UniProtKB:P04049-1, Ser-338/Ser-339, MOD:00046.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that has been phosphorylated on the two 14-3-3 binding sites. Example: UniProtKB:P04049-1, Ser-259/Ser-621, MOD:00046.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated form

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that includes at least one phosphorylated residue.


name: RAS guanyl-releasing protein 1 isoform h2 (human)

description: A RAS guanyl-releasing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O95267-2.


name: long-wave-sensitive opsin 1 sequence variant P307L (human)

description: A long-wave-sensitive opsin 1 (human) that has a Leu residue at the position equivalent to Pro-307 of the amino acid sequence represented by UniProtKB:P04000. UniProtKB:P04000, Pro-307, CHEBI:30006.


name: OPSR_HUMAN Long-wave-sensitive opsin 1 (sprot)

description: A long-wave-sensitive opsin 1 that is encoded in the genome of human.


name: long-wave-sensitive opsin 1 sequence variant C203R (human)

description: A long-wave-sensitive opsin 1 (human) that has an Arg residue at the position equivalent to Cys-203 of the amino acid sequence represented by UniProtKB:P04000. UniProtKB:P04000, Cys-203, CHEBI:29952.


name: long-wave-sensitive opsin 1 sequence variant G338E (human)

description: A long-wave-sensitive opsin 1 (human) that has a Glu residue at the position equivalent to Gly-338 of the amino acid sequence represented by UniProtKB:P04000. UniProtKB:P04000, Gly-338, CHEBI:29972.


name: histone H3.1, initiator methionine removed symmetrically-dimethylated 1 (human)

description: A histone H3.1 (human) that has had the initiator methionine removed and that has been symmetrically-dimethylated on the residue at the position equivalent to Arg-9 of the amino acid sequence represented by UniProtKB:P68431. UniProtKB:P68431, 2-136, Arg-9, MOD:00076.


name: tissue factor pathway inhibitor isoform Beta (human)

description: A tissue factor pathway inhibitor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P10646-2.


DTPD_ECOLI Dipeptide permease D (sprot)

A dipeptide permease D that is encoded in the genome of Escherichia coli K-12.


dipeptide permease D

A protein that is a translation product of the Escherichia coli K-12 dtpD gene or a 1:1 ortholog thereof.


name: PTR45_ARATH Protein NRT1/ PTR FAMILY 5.7 (sprot)

description: A dipeptide permease D that is encoded in the genome of Arabidopsis thaliana.


aldehydo-L-mannose

The L-enantiomer of aldehydo-mannose.


name: Grade 4 Oral Cavity Mucositis or Stomatitis by Clinical Examination Classification, CTCAE


name: serine/Arginine-related protein 53 isoform h2 (human)

description: A serine/Arginine-related protein 53 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96IZ7-2.


name: ODP2_DICDI Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial (sprot)

description: A dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial that is encoded in the genome of Dictyostelium discoideum.


name: cyclin-dependent kinase inhibitor 2A, isoforms h1/h2/h3/h5 sequence variant P81R (human)

description: A cyclin-dependent kinase inhibitor 2A, isoforms h1/h2/h3/h5 (human) that has an Arg residue at the position equivalent to Pro-81 of the amino acid sequence represented by UniProtKB:P42771-1. Example: UniProtKB:P42771-1, Pro-81, CHEBI:29952.


name: Pre-Existing Type 2 Diabetes Mellitus, in Pregnancy, Second Trimester

description: Evidence of pre-existing type 2 diabetes mellitus in the in pregnancy in the second trimester.


name: FAMA_ARATH Transcription factor FAMA (sprot)

description: A protein that is a translation product of the FAMA gene in Arabidopsis thaliana.


name: DNA repair protein complementing XP-C cells isoform h2 (human)

description: A DNA repair protein complementing XP-C cells (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q01831-2.


protein FlxA

A protein that is a translation product of the Escherichia coli K-12 flxA gene or a 1:1 ortholog thereof.


FLXA_ECOLI Protein FlxA (sprot)

A protein FlxA that is encoded in the genome of Escherichia coli K-12.


Hernández-Aguirre Negrete syndrome

description: A syndrome is characterized by major seizures, dysmorphic features (round face, bulbous nose, wide mouth, prominent philtrum), pes planus, psychomotor retardation and obesity. It has been described in five children (three boys and two girls, one of whom died in infancy) from two unrelated Mexican families. This condition is likely to be transmitted as an autosomal recessive trait.


name: F-box/WD repeat-containing protein 1A methylated 1 (human)

description: An F-box/WD repeat-containing protein 1A (human) that has been methylated on the residue at the position equivalent to Cys-137 of the amino acid sequence represented by UniProtKB:Q9Y297-1. Example: UniProtKB:Q9Y297-1, Cys-137, MOD:00660.


name: versican core protein O-glycosylated 117 (human)

description: A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-1569 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-1569, MOD:00005~GNO:G43417UB.


N-undecanoylglycine

An N-acylglycine with an acyl group that is undecanoyl.


name: RN19B_HUMAN E3 ubiquitin-protein ligase RNF19B (sprot)

description: An E3 ubiquitin-protein ligase RNF19B that is encoded in the genome of human.


name: E3 ubiquitin-protein ligase RNF19B isoform h4 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-4.


name: E3 ubiquitin-protein ligase RNF19B deaminated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been deaminated on the residue at the position equivalent to Gln-720 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Gln-720, MOD:00685.


name: E3 ubiquitin-protein ligase RNF19B isoform h1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-1.


name: E3 ubiquitin-protein ligase RNF19B methylated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been methylated on the residue at the position equivalent to Cys-203 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Cys-203, MOD:00660.


name: E3 ubiquitin-protein ligase RNF19B isoform h3 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-3.


name: E3 ubiquitin-protein ligase RNF19B cysteinylated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been cysteinylated on the residue at the position equivalent to Cys-203 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Cys-203, MOD:00765.


name: E3 ubiquitin-protein ligase RNF19B cysteinylated 2 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been cysteinylated on the residue at the position equivalent to Cys-695 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Cys-695, MOD:00765.


name: E3 ubiquitin-protein ligase RNF19B phosphorylated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been phosphorylated on the residue at the position equivalent to Ser-270 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Ser-270, MOD:00046.


name: E3 ubiquitin-protein ligase RNF19B isoform h2 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-2.


Secretory Depletion

description: Decreased secretory content (e.g., mucus or granules) in secretory cells.


Pathology Result

description: The outcome of a pathologic examination.


Ectopic Tissue

description: A tissue that forms in a location of the body at or in which it is not normally associated.


No Identifiable Line of Differentiation

description: A laboratory finding indicating that the line of differentiation in a cellular infiltrate cannot be identified.


Fibrotic Stroma Formation

description: A morphologic finding that indicates the presence of reactive fibrotic stroma in a tissue sample.


name: Focus of Carcinoma Cells Measuring Equal to or Less Than 2 cm Present

description: A morphologic finding indicating the presence of a component of carcinoma cells that measures equal to or less than 2 cm in greatest dimension.


Atypia

description: The condition of being irregular or not conforming to type.


Neck soft tissue necrosis

description: A necrotic process affecting the soft tissues of the neck.


Connective Tissue Alteration

description: Connective Tissue Alteration involves a qualitative change in the existing state of supporting tissue derived from mesenchyme that binds other tissues and consists of various cell types embedded in a fibrous and ground substance extracellular matrix.


CD30-Positive Neoplastic Cells Present

description: A finding that a sample of neoplastic cells has detectable immunoreactivity for CD30 (TNFRSF8).


PD-L1 Expression Less than 50 Percent

description: An immunohistochemical finding indicating that less than 50 percent of the cells in a sample are expressing PD-L1.


Increased Corticomedullary Ratio

description: Increase in the size of the cortex relative to the medulla.


High Grade Dysplasia

description: A subjective characterization of the phenomenon of dysplasia, based on microscopic examination of the architectural and/or cytological changes in a tissue sample, that is determined to be high.


name: Glucagon-Like Peptide Positive Neoplastic Cells Present


Osseous metaplasia

description: Heterotopic formation of normal bone within soft tissue.


name: Invasive Focus of Carcinoma Cells Measuring More Than 5 mm Present

description: A morphologic finding indicating the presence of an invasive component of carcinoma cells that measures more than 5 mm in greatest dimension.


CSF Blasts Present

description: An indication that blasts were found in the cerebrospinal fluid sample.


name: Estrogen Receptor Positive by Immunohistochemistry 61-70 Percent

description: An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing estrogen receptor.


Microcystic Growth Pattern

description: A morphologic finding where cells show numerous small cyst-like spaces that vary in size creating a sieve-like appearance.


CD19-Positive Neoplastic Cells Present

description: An immunophenotypic finding indicating that expression of CD19 has been detected in a sample of neoplastic cells.


name: Well Differentiated Hyaline Cartilage Present


Cribriform Pattern

description: A morphologic finding indicating the presence of sheets of malignant epithelial cells punctuated by gland-like spaces in a tissue sample.


Negative for Neoplasia

description: A microscopic finding indicating the absence of neoplastic cells in a tissue sample.


Hypopharyngeal Epithelial Dysplasia

description: Mild, moderate, or severe dysplasia of the squamous epithelium of the hypopharyngeal mucosa.


Karyorrhexis

description: Degeneration of the cell nucleus marked by contraction of the chromatin into small pieces and loss of the nuclear boundary.


Supernumerary Lobe

description: More than the usual or expected number of lobes.


name: PD-L1 Combined Positive Score Less than 5

description: A semi-quantitative immunohistochemical finding indicating that the number of all PD-L1-expressing cells divided by the total number of viable tumor cells in a sample multiplied by 100 is less than 5.


Solid Growth Pattern

description: A microscopic finding indicating that the neoplastic cells are arranged in solid sheets in a tumor sample.


Maturation Asynchrony Present

description: A morphologic finding indicating lack of synchronous maturation of the cytoplasm and the nucleus.


name: Ki-67 Positive Cells Greater than or Equal to 3 Percent

description: A semi-quantitative microscopic finding indicating that at least 3 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


Myxoid Stroma Formation

description: A morphologic finding that indicates the presence of myxoid changes in the stroma of a tissue sample.


Cellular Debris

description: An accumulation of cell fragments.


Villous Pattern

description: A morphological appearance resembling the villi seen on the mucosa of the small bowel


name: Sparsely Cellular Collagenised Areas Present


name: Neoplastic Cells with Bright CD56 Expression Present

description: An immunophenotypic finding indicating the presence of neoplastic cells with bright CD56 expression.


name: Curvilinear Thin-Walled Vascular Pattern


name: Marked Distention of Terminal Duct Lobular Units Present

description: A morphologic finding indicating the presence of terminal duct lobular units with significant distention in a breast tissue sample.


Tumor Invasion of the Mucosa

description: A finding indicating that a neoplastic cellular infiltrate has broken the basement membrane and invaded the lamina propria.


name: PD-L1 Combined Positive Score Greater than or Equal to 1

description: A semi-quantitative immunohistochemical finding indicating that the number of all PD-L1-expressing cells divided by the total number of viable tumor cells in a sample multiplied by 100 is at least 1.


MSH6 Nuclear Expression Intact

description: An indication that expression of MSH6 was detected in the nuclei of cells in a sample.


Prominent Schwannian Stroma Present

description: A finding indicating the presence of a Schwann cell-rich stromal component in a neoplastic tissue specimen.


Large Cell Dysplasia

description: A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with enlarged nuclei and cytoplasm, nuclear pleomorphism, multinucleation, and hyperchromasia.


Concordant Bone Marrow Histology

description: A finding, usually associated with lymphoma with bone marrow involvement, where the morphology observed in the bone marrow is the same as that found in the primary nodal site.


Mean Staining Intensity

description: The mean of the degree or magnitude of staining within a biological specimen.


Upper Limb Soft Tissue Necrotic Lesion

description: A necrotic process affecting the soft tissues of the upper extremity.


Intramucosal Lesion

description: A pathologic process that is confined to the mucosa.


Seroma

description: A collection of serum in the body.


Intestinal metaplasia of gastric mucosa

description: A morphologic finding indicating the replacement of part of the gastric mucosal epithelium with intestinal-type epithelium.  Using immunohistochemical staining, gastric intestinal metaplasia is classified as complete or incomplete.  Complete intestinal metaplasia is defined by the decreased expression of gastric mucins and expression of the intestinal mucin MUC2.  Incomplete intestinal metaplasia is defined by the co-expression of both gastric mucins and MUC2.


Astrocyte Swelling And Vacuolation

description: A morphologic finding indicating the presence of astrocytes with intracytoplasmic swelling and vacuolation.


Perivascular Lymphocytic Infiltrate

description: A morphologic finding indicating the presence of a non-neoplastic or neoplastic lymphocytic infiltrate surrounding vessels.


Small Cell Component Present

description: A morphologic finding that refers to the presence of a small cell component in a cellular infiltrate.


Pleural/Elastic Layer Invasion

description: A pathologic finding indicating the extent of visceral pleural invasion by a malignant neoplasm.


name: progressive transformation of germinal centers

description: Progressive transformation of germinal centers is a condition in which a lymph node becomes very enlarged (lymphadenopathy). Typically, only one lymph node is affected, though PTGC can involve multiple lymph nodes. Theneck is the most common location of affected lymph nodes, but PTGC may also affect lymph nodes in the groin and armpits. adults are more frequently affected than children, but children have a higher chance of developing PTGC multiple times (recurrence). PTGC is not considered a precancerous condition, though it has been associated with Hodgkin lymphoma.


name: Ki-67 Positive Cells Greater than 20 Percent

description: A semi-quantitative microscopic finding indicating that more than 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


name: Small Capillary-Sized Vascular Proliferation


Zonal necrosis

description: A morphologic finding referring to the presence of necrosis that is confined to a specific anatomic zone. Representative example is the hepatic zonal necrosis that affects the hepatic parenchyma either in the portal areas or around the hepatic veins.


Staining Intensity 0-1+

description: A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0 or 1+.


Extensive Extracapsular Extention

description: A morphological finding indicating that the tumor cell invasion outside the lymph node capsule was greater than 1 mm.


CD45-Positive Neoplastic Cells Present

description: An immunophenotypic finding indicating that expression of CD45 has been detected in a sample of neoplastic cells.


Ductopenia

description: A morphologic finding indicating reduction in the numbers of interlobular and septal bile ducts in the liver tissue.


name: Pancreatobiliary-Type Malignant Cells Present

description: A morphologic finding indicating the presence of malignant cells with a phenotype that resembles the malignant cells of the pancreatic ductal or extrahepatic bile duct carcinomas.


Intraepithelial Neutrophils Present

description: A morphologic finding indicating the presence of neutrophils within neoplastic or non-neoplastic epithelium.


name: Growth Hormone and Prolactin-Producing Neoplastic Cells Present

description: An immunohistochemical finding indicating the presence of growth hormone and prolactin producing cells in a tumor.


Serrated Glandular Architecture

description: The common saw-tooth architectural pattern observed within hyperplastic polyps.


name: Spaces Lined by One to Three Layers of Monotonous Atypical Cells Present


PD-L1 Immune Cell Score

description: The percentage of the tumor area infiltrated by PD-L1 positive immune cells as determined by immunohistochemical staining.


Hypertrophy and Karyomegaly

description: A finding of both hypertrophy and karyomegaly in the same lesion.


Florid Follicular Hyperplasia

description: A morphologic finding indicating the presence of prominent follicular hyperplasia in a lymph node sample.


Osteoblastic Rimming Present

description: A morphologic finding indicating the presence of bony trabeculae rimmed with osteoblasts.


Hypersegmented Neutrophils Present

description: A morphologic finding indicating the presence of neutrophils with five or more nuclear lobes. It is seen in macrocytic anemias caused by B12 or folic acid deficiency.


Basal Decidual Karyorrhexis

description: Collections of degenerated nuclear fragments that are associated with tissue injury during placental abruption.


PD-L1 Positive

description: An immunohistochemical test result that indicates expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.


Malignant Primitive Cellular Infiltrate

description: A morphologic finding indicating the presence of a malignant primitive cellular infiltrate in a tissue sample.


name: Post-radiation cytologic changes with dysplasia


Incomplete Tumor Cell Necrosis

description: A morphologic finding indicating the presence of focal or diffuse tumor cell necrosis involving part of the neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are still present.


Oligodendroglial Component Present

description: A tumor component characterized by the presence of a diffuse, homogeneous population of tumor cells (oligodendroglial cells) with round nuclei and clear cytoplasm.  The infiltrate has a honeycomb appearance.  An oligodendroglial component can be seen in central nervous system tumors including glioblastomas and mixed gliomas.


name: Progesterone Receptor Positive by Immunohistochemistry Less than 10 Percent

description: An immunohistochemical staining finding indicating that less than 10 percent of the cells in a tissue sample are expressing progesterone receptor.


Locally Invasive Lesion

description: A lesion composed of tumor cells invading the surrounding tissues without evidence of wide tumor spread.


Epithelial metaplasia

description: A morphologic finding that refers to the replacement of a group of one type of epithelial cells (e.g., glandular epithelial cells) to another type of epithelial cells (e.g., squamous epithelial cells).


name: Entrapped Respiratory Epithelium Present


CD20-Positive Neoplastic Cells Present

description: An immunophenotypic finding indicating that expression of CD20 has been detected in a sample of neoplastic cells.


name: Undifferentiated "Fetal-Type" Tissues Present


Staining Intensity 1+

description: A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.


name: Percent Follicular Component Greater than 10 Percent

description: A semi-quantitative microscopic finding indicating more than 10 percent of the area of a tissue section has follicular structures.


name: Marked Thickening of the Bladder Urothelium Present

description: A morphologic finding indicating the presence of marked thickening of the urothelium in the bladder.


Megaloblastoid Changes Present

description: A morphologic finding indicating the presence of abnormally large nucleated erythroblasts in the bone marrow.


name: Malignant Glandular Epithelium Resembling the Normal Endometrium Present


Endometrial metaplasia

description: A morphologic finding indicating the alteration of the mature endometrial glandular epithelium to another that differs from that of normal endometrioid glands.


name: Cysts Containing Proteinaceous Fluid Present


Foveolar-Type Epithelium Present

description: A morphologic finding indicating the presence of foveolar-type epithelial cells in a tissue sample.


name: Ki-67 Positive Cells Greater than 10 Percent

description: A semi-quantitative microscopic finding indicating that greater than 10 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


name: Arborising Network of Cords of Basaloid Cells Present


name: Tumor-Associated Peptide Antigens Present

description: An indication that expression of part or all of a study-specific panel of tumor-associated peptide antigens has been detected in a sample.


Increased Hassall's Corpuscles

description: A morphologic finding indicating the presence of an increased number of Hassall's corpuscles in the thymus gland.


name: Somatostatin-Positive Neoplastic Cells Present


Bilayer Pattern

description: A morphologic finding indicating the presence of a two-layer cellular structure in a tissue sample.


Deposit

description: Accumulation of extraneous inorganic matter in tissues or cavities.


Predominantly Fibroglandular Tissue

description: A finding indicating that the predominant components in a tissue sample are fibrous and glandular elements.


name: Progesterone Receptor Positive by Immunohistochemistry 11-20 Percent

description: An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing progesterone receptor.


Wedge-Shaped Growth Pattern

description: A morphologic architectural pattern in which the tumor cells spread in a wedge-shaped pattern.


cervical metaplasia

description: Metaplastic changes in the cervical glandular or squamous epithelium.


Nodular Pattern

description: A morphologic architectural pattern characterized by the presence of proliferating non-neoplastic or neoplastic cells forming single or multiple nodules within a lesion.


Decreased Cellularity Present

description: A decrease in the number of cells as compared to a standard or norm.


CD43-Positive Neoplastic Cells Present

description: An indication that expression of CD43 has been detected in a sample of neoplastic cells.


Molecular Pathology Test Result

description: The outcome of a molecular pathology assay.


name: CD33 Expression 20 Percent or More of Neoplastic Cells

description: A semi-quantitative immunochemistry finding indicating that expression of CD33 was detected in at least 20 percent of the cells in a tumor sample.


Heterogeneous Morphology

description: A finding indicating the presence of two or more distinct neoplastic cellular components in a tissue sample.


Submucosal 3 Invasion

description: Submucosal tumor invasion into the lower third of the submucosal tissue.


Histopathology Result

description: A finding resulting from the examination of a tissue sample under light or electron microscopy.


name: Low Phospho-AKT Immunohistochemical Expression


name: Fascicles of Spindly Tumor Cells Present


Cystic Change

description: A microscopic finding indicating the formation of cystic structures in a tissue sample.


Microvascular Proliferation

description: A morphological finding indicating the presence of newly formed blood vessels comprised of smooth muscle cells, pericytes and hyperplastic endothelial cells.


name: Superficial Monoclonal T-Cell Infiltrate Present in Gastrointestinal Tract

description: A finding indicating the presence of a superficial monoclonal T-lymphocytic infiltrate in the gastrointestinal tract.


Inclusion Body

description: A detectable aggregation of substance in the cytoplasm or nucleus.


Vascular Endothelial Proliferation

description: A question as to whether vascular endothelial proliferation was present.


name: Progesterone Receptor Positive by Immunohistochemistry 61-70 Percent

description: An immunohistochemical staining finding indicating that 61-70 percent of the cells in a tissue sample are expressing progesterone receptor.


Granulation Tissue

description: Vascular connective tissue formed on the surface of an ulcer or healing wound.


Helicobacter Present

description: The presence of any species of Helicobacter.


name: TACSTD2 Expression by Immunohistochemistry Greater than or Equal to +1

description: An indication that the immunohistochemical staining intensity detected in a sample for TACSTD2 was at least +1.


Labyrinthine Growth Pattern

description: A morphologic finding where cells are arranged in the form of a maze.


name: Pseudostratified Columnar Tumor Cells Present


Heinz Body

description: Intracellular red blood cell inclusions comprised of denatured hemoglobin.


Eosinophilic Infiltrate

description: An inflammatory infiltrate composed exclusively or predominantly of eosinophils.


Mild Immune Presence

description: Approximately 10-20 percent of the tissue surface area is occupied by immune cell infiltration.


Basal Decidual Necrosis

description: Acellular areas of the basal plate.


Venous Invasion

description: A term referring to the presence of tumor emboli or tumor masses within veins.


name: Intestinal Metaplasia of Columnar Epithelium

description: A morphologic finding indicating the replacement of part of the columnar epithelium by intestinal-type epithelium.


Transitional cell metaplasia

description: A morphologic finding that refers to the replacement of non-transitional epithelium (e.g., squamous epithelium) with transitional epithelium.


name: Pseudostratified Neuroepithelial Tumor Cells Present


CD4-Positive Neoplastic Cells Present

description: An indication that expression of CD4 has been detected in a sample of neoplastic cells.


name: Dilated Terminal Duct Lobular Units Present

description: A morphologic finding indicating the presence of dilated terminal duct lobular units in a breast tissue sample.


Palisading Necrosis

description: A morphologic appearance consisting of small, irregular regions of necrosis surrounded by dense accumulations of tumor cells; the tumor cells are more densely packed at the edge of the necrosis than in other regions of the tumor and thus appear to "palisade" around the necrotic zone.


Spongiosis

description: A morphologic finding referring to the presence of intercellular edema in the epidermal keratinocytes or to the vacuolization of the central nervous system white matter.


Microinvasive tumor

description: Minimal invasion by malignant cells of the tissues that are immediately adjacent to a carcinoma in situ.


name: Increased Melanin Pigmentation in Basal Keratinocytes Present

description: A morphologic finding indicating the presence of increased melanin-pigmentation in basal keratinocytes in a skin tissue sample.


name: Melanocytes Near the Tips and Sides of Elongated Rete Ridges Present


name: Mixture of Melanocytic Neoplastic Components Present

description: A  finding indicating the presence of at least two morphologic components in a melanocytic tumor sample.


Focal Pattern

description: A morphologic architectural pattern in which a cellular population is distributed in a localized or relatively uneven fashion throughout a specified tissue area; not diffuse.


name: Low Grade Cartilaginous Component Present


Inflammatory Infiltrate

description: A microscopic finding indicating the presence of acute, subacute or chronic inflammation in a tissue sample.


Between 3 and 9 Mitoses per 10 HPF

description: A microscopic finding indicating the presence of at least three and at most nine mitotic figures per ten high power fields in a sample.


D2C7 3+ Staining

description: A finding of 3+ staining with D2C7 monoclonal antibody in a sample.


Decreased Colloid

description: Decrease in the amount of colloid.


Immunohistochemical Status of PD-L1

description: An immunohistochemical test result that refers to the overexpression or lack of expression of PD-L1 in a tissue sample of a primary or metastatic malignant neoplasm.


nephrogenic adenoma

description: So-called nephrogenic adenoma is a distinct metaplastic lesion of the urothelium characterized by aggregates of cuboidal or hobnail cells. These cells line thin papillary fronds on the surface or form tubular structures within the lamina propria.


Gross Pathology Result

description: The outcome of a gross, or macroscopic, pathologic examination.


Increased Peri-Insular Halos

description: Increased number and/or size of peri-insular halos.


Moderate Dysplasia

description: A morphologic finding indicating the presence of moderate cellular atypia associated with moderate architectural changes in a tissue sample.


name: Estrogen Receptor Positive by Immunohistochemistry 11-20 Percent

description: An immunohistochemical staining finding indicating that 11-20 percent of the cells in a tissue sample are expressing estrogen receptor.


Low Grade Oral Epithelial Dysplasia

description: Dysplasia in the oral cavity with low grade architectural and cytological epithelial changes.


Ischemic Necrosis

description: Loss of vascularization and tissue death caused by the disruption in the arterial access. Common causes include trauma due to accidents, insect or reptile bites, severe cold exposure or pathological conditions such as infarctions or blood dyscrasias.


Complete Tumor Cell Necrosis

description: A morphologic finding indicating the presence of tumor cell necrosis involving the entire neoplastic cellular infiltrate in a tissue sample. Viable tumor cells are absent.


Aberrant Thyroid Tissue Present

description: A morphologic finding indicating the presence of thyroid tissue in an organ unrelated to thyroid gland.


name: Ki-67 Positive Cells Greater than or Equal to 10 Percent

description: A semi-quantitative microscopic finding indicating that at least 10 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


name: Estrogen Receptor Positive by Immunohistochemistry 31-40 Percent

description: An immunohistochemical staining finding indicating that 31-40 percent of the cells in a tissue sample are expressing estrogen receptor.


Deep Tissue Invasion

description: Expansion of a malignant cellular infiltrate far downward into the soft tissues.


name: Cowdry Type A Eosinophilic Intranuclear Inclusion


name: Diffuse Proliferation of Pulmonary Neuroendocrine Cells Present

description: A morphologic finding indicating the presence of a diffuse proliferation of neuroendocrine cells in the lung parenchyma.


Squamous Metaplasia Without Atypia

description: A morphologic finding indicating the transformation of glandular or transitional epithelial cells to squamous epithelial cells that lack atypical features.


Tall Papillae Present

description: A morphologic growth pattern indicating the presence of tall papillary structures.


name: Perineuronal and/or Perivascular Satellitosis

description: A morphologic finding that refers to the accumulation of glial cells encircling neurons and/or vessels in a tissue specimen.


Angioinvasion

description: A term referring to the presence of tumor emboli or tumor masses within blood vessels (arteries or veins).


PD-L1 Status Unknown

description: Indicates that the immunohistochemical test result for PD-L1 is unknown or the test has not been performed.


Pigmented Dendritic Melanocytes Present

description: A morphologic finding indicating the presence of pigmented dendritic melanocytes in a tissue sample.


Apocrine Differentiation

description: A morphologic finding that indicates the presence of cells with abundant eosinophilic and granular cytoplasm in a tumor sample.


HPV-Reactive T-Cell Finding

description: A finding indicating the presence, absence or amount of T-cells in a sample that specifically react to human papillomavirus-derived antigens.


Cytologic atypia

description: The presence of irregularly shaped or sized cells as compared to the cells that are normally present.


Positive Surgical Margin

description: Indicates the presence of tumor cells at the edge of a surgically excised specimen.


Necrotic Change

description: A finding indicating the presence of cellular necrosis in a tissue specimen.


Lymphoplasmacytic Infiltrate

description: A finding referring to the presence of a cellular infiltrate that is composed of lymphocytes and plasma cells in a tissue sample.


name: Single Type of Tissue Derived from One Embryonic Layer Present


Myofibroblastic Differentiation

description: A morphologic finding that indicates the presence of myofibroblastic differentiation in a cellular infiltrate of a tissue sample.


name: Ki-67 Positive Cells Greater than or Equal to 30 Percent

description: A semi-quantitative microscopic finding indicating that at least 30 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


name: Poor Tissue Fixation with No Definable Features


name: Cartilaginous Metaplasia of Malignant Cells Present


Adipose Tissue Deposition

description: The deposition of lipids in tissue.


Cervical atypism

description: Irregularity or alteration from normal cervical tissue. The spatial orientation of the cervical cells is often aberrant due to the lack of an organized growth process. 2005


Epithelial Damage

description: A morphologic finding indicating the presence of epithelial changes in a tissue sample that result from a pathologic process.


name: Barrett Esophagus With Metaplastic Non-Goblet Cell Columnar Epithelium

description: A finding in an esophageal biopsy specimen indicating the diagnosis of Barrett esophagus associated with the presence of metaplastic non-goblet cell columnar epithelium.


Gallbladder necrosis

description: A necrotic process occurring in the gallbladder.


TP53 Loss of Nuclear Expression

description: An indication that expression of TP53 was not detected in the nuclei of cells in a sample.


name: Endometrial Type Glands and Stroma Present


Cadmium Deposition

description: A finding indicating the presence of cadmium mineral deposits in an organ.


Clark Level III

description: A morphologic finding indicating that the cutaneous melanoma has invaded the entire thickness of the papillary dermis but the malignant cellular infiltrate does not extend into the reticular dermis.


Ki-67 Positive Cells 15 Percent or Less

description: A semi-quantitative microscopic finding indicating that 15 percent or less of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


name: Enterochromaffin-Like Type Granules Present


Anaplasia

description: A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.


name: PSMA-Positive Extracellular Vesicles Low

description: An indication that extracellular vesicles expressing PSMA (PSMA-EVs) were found at low concentrations in a sample. Low levels of PSMA-EVs are seen in samples from subjects with non-metastatic urologic neoplasms.


name: Ki-67 Positive Cells Greater than or Equal to 20 Percent

description: A semi-quantitative microscopic finding indicating that at least 20 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


description: A morphologic finding indicating the presence of acinar and tubular differentiation  in a tissue sample of an epithelial neoplasm.


Occasional Macrophages Present

description: A morphologic finding indicating the presence of occasional macrophages in a tissue sample.


name: Human Papillomavirus-Related Oral Epithelial Dysplasia

description: Oral epithelial dysplasia caused by human papillomavirus infection. The tongue, floor of mouth, and buccal mucosa are the most commonly affected sites. It is characterized by the presence of mucosal dysplasia with prominent karyorrhectic/apoptotic cells. There is a risk of progression to squamous cell carcinoma.


CD33-Positive Neoplastic Cells Present

description: An immunophenotypic finding indicating that expression of CD33 has been detected in a sample of neoplastic cells.


H Score Staining Intensity 0

description: A measurement of the amount or proportion of cells that have a staining intensity of 0, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).


Limited Early T-Cell Differentiation

description: A finding indicating the presence of neoplastic cells with immunophenotypic and genetic characteristics suggesting limited early T-cell differentiation.


name: Well Developed Rough Endoplasmic Reticulum Present


name: Fully Differentiated "Adult-Type" Tissues Present


Trabecular Pattern

description: A microscopic finding indicating that the neoplastic cells are arranged in trabeculae in a tumor sample.


name: Estrogen Receptor Positive by Immunohistochemistry 81-90 Percent

description: An immunohistochemical staining finding indicating that 81-90 percent of the cells in a tissue sample are expressing estrogen receptor.


Central Nervous System Necrotic Lesion

description: A necrotic process affecting the brain and/or spinal cord.


H Score Staining Intensity 1+

description: A measurement of the amount or proportion of cells that have a staining intensity of 1+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).


name: Ki-67 Positive Cells Less than 10 Percent

description: A semi-quantitative microscopic finding indicating that less than 10 percent of the cells in a sample are detected following staining using an anti-Ki-67 antibody.


Nodule Internal Feature

description: A characteristic associated with a nodule that is found within the nodule itself.


Endometrioid Tissue Present

description: A microscopic finding indicating the presence in a sample of tissue that resembles endometrial tissue.


name: Absence of Invasion or Limited Invasion Present


name: Neoplastic Cells with Granular, PAS-Positive Cytoplasm Present

description: A morphologic finding indicating the presence of a cellular infiltrate composed of neoplastic cells with granular, PAS-positive cytoplasm in a tissue sample.


Syncytial Pattern

description: A morphologic growth pattern in which the neoplastic cells form sheets, are intimately close to each other, and lack distinguishable cell membranes.


name: TACSTD2 Expression by Immunohistochemistry 2+

description: An indication that the immunohistochemical staining intensity detected in a sample for TACSTD2 was 2+.


Keratin Present

description: A morphologic finding indicating the presence of keratin in a tissue sample.


PMS2 Nuclear Expression Intact

description: An indication that expression of PMS2 was detected in the nuclei of cells in a sample.


Increased Cellular Aggregates

description: Increase in the number or size of aggregates.


Staining Intensity 0

description: A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.


Necrosis and Inflammation

description: A morphologic finding indicating the presence of necrosis associated with an inflammatory infiltrate in a tissue sample.


name: Hemorrhagic Neuroblastic Nodules Present


Abdominal Soft Tissue Necrotic Lesion

description: A necrotic process occurring in the soft tissues of the abdominal wall.


Lepidic Growth Pattern

description: A morphologic finding indicating that the neoplastic cells have proliferated along the surface of intact alveoli without stromal or vascular invasion.


Decreased Peri-Insular Halos

description: Decreased number and/or size of peri-insular halos.


Bone Marrow Blasts Morphology

description: The morphology characteristics of the bone marrow blasts.


name: Progesterone Receptor Positive by Immunohistochemistry 21-30 Percent

description: An immunohistochemical staining finding indicating that 21-30 percent of the cells in a tissue sample are expressing progesterone receptor.


Clark Level Finding

description: A morphologic finding indicating the cutaneous melanoma depth of invasion into the dermis and subcutaneous tissue.


Focal Cortical Dysplasia Type 2

description: Focal cortical dysplasia characterized by disrupted cortical lamination and specific cytological abnormalities. It includes type IIa with dysmorphic neurons and type IIb with dysmorphic neurons and balloon cells.


Perineural Invasion

description: A morphologic finding referring to a tumor that has spread along and infiltrated nerve fibers.  The presence of perineural invasion by malignant tumor cells may represent a poor prognostic factor.


Increased Mucification Present

description: A finding indicating an increase in the numbers of epithelial cells that have been transformed into mucus-secreting cells. This does not include the normal increase in mucification seen in the estrous cycle.


name: TACSTD2 Expression by Immunohistochemistry 3+

description: An indication that the immunohistochemical staining intensity detected in a sample for TACSTD2 was 3+.


name: PD-L1 Expression Greater than 50 Percent

description: An immunohistochemical finding indicating that more than 50 percent of the cells in a sample are expressing PD-L1.


Tuboendometrioid Metaplasia

description: Replacement of the endocervical-type epithelium of the cervix by benign tubal or endometrioid epithelium.


Crohn Disease-Like Reaction

description: A distinctive Crohn's disease-like reaction (CLR) consisting of discrete lymphoid aggregates, some with germinal centers, and surrounding stellate fibrosis commonly found around colorectal adenocarcinomas in the absence of clinical or pathologic evidence of prior Crohn's disease.


name: Progesterone Receptor Positive by Immunohistochemistry 1-10 Percent

description: An immunohistochemical staining finding indicating that 1-10 percent of the cells in a tissue sample are expressing progesterone receptor.


MSH6 Loss of Nuclear Expression

description: An indication that expression of MSH6 was not detected in the nuclei of cells in a sample.


Apoptosis and Single Cell Necrosis

description: A finding that generally has features of apoptosis and single cell necrosis.


Dense Collagenized Tissue Present

description: A morphologic finding indicating the presence of a dense, collagenous stroma associated with a cellular infiltrate in a tissue sample.


Large Nested Pattern

description: A microscopic finding indicating that the neoplastic cells are arranged in large compact nests in a tumor sample.


Coagulative necrosis

description: Ischemic tissue necrosis characterized by the preservation of the architectural pattern and a necrotic ghost appearance of the cells.


name: Non Lipogenic Sarcomatous Stroma Present


MSH2 Loss of Nuclear Expression

description: An indication that expression of MSH2 was not detected in the nuclei of cells in a sample.